发明名称 |
COMBINATION OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR |
摘要 |
The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases. |
申请公布号 |
US2017095463(A1) |
申请公布日期 |
2017.04.06 |
申请号 |
US201615335957 |
申请日期 |
2016.10.27 |
申请人 |
Fritsch Christine;Garcia-Echeverria Carlos;Huang Xizhong;Maira Sauveur-Michel |
发明人 |
Fritsch Christine;Garcia-Echeverria Carlos;Huang Xizhong;Maira Sauveur-Michel |
分类号 |
A61K31/4439;A61K45/06;A61K31/436 |
主分类号 |
A61K31/4439 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical combination comprising
a) a compound (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and b) at least one mTOR inhibitor which is everolimus (RAD001), or a pharmaceutically acceptable salt thereof. |
地址 |
Steinbach FR |